CCNE1

G1/S-specific cyclin-E1

186,152 patent compounds predicted against CCNE1, 110,754 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL103715	0.66	19/20
SCHEMBL12466	0.58	16/20
SCHEMBL12292	0.59	15/20
SCHEMBL268925	0.50	14/20
SCHEMBL269583	0.50	14/20
SCHEMBL179490	0.52	13/20
SCHEMBL160631	0.40	11/20
Clonazepam (SCHEMBL38899)	0.59	10/20
SCHEMBL285629	0.65	9/20
SCHEMBL239486	0.34	9/20
SCHEMBL240231	0.34	9/20
Bms-387032 (SCHEMBL187401)	1.00	8/20
SCHEMBL183185	0.55	8/20
SCHEMBL186141	0.50	8/20
SCHEMBL84453	0.48	8/20
Seliciclib (SCHEMBL94728)	1.00	7/20
(Rs)-Roscovitine (SCHEMBL172593)	1.00	7/20
SCHEMBL183273	0.58	7/20
SCHEMBL91448	0.47	7/20
SCHEMBL37886	0.45	7/20

Germline variants in CCNE1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CCNE1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CCNE1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	PHASE2	COMPLETED
Study of AVZO-021 in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients	PHASE2	COMPLETED
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification	PHASE2	COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas	PHASE2	RECRUITING
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	PHASE1/PHASE2	RECRUITING
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors	PHASE2	WITHDRAWN
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency	PHASE2	COMPLETED
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)	PHASE2	COMPLETED
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma	PHASE2	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors	PHASE1	RECRUITING
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	WITHDRAWN
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck	PHASE1	COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)	PHASE1	COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors	PHASE1	WITHDRAWN
Study of SGR-3515 In Participants With Advanced Solid Tumors.	PHASE1	RECRUITING
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma	PHASE1	WITHDRAWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy	nan	UNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCNE1 binder may also engage these)

Protein	Name	Similarity
Q61457	—	0.998	Q61457 →
P49707	—	0.997	P49707 →
P39949	—	0.997	P39949 →
P50756	—	0.995	P50756 →
Q91780	—	0.995	Q91780 →
O15995	—	0.993	O15995 →
O42575	—	0.993	O42575 →
P47794	—	0.993	P47794 →
CCNE2	G1/S-specific cyclin-E2	0.992	landscape →
Q9Z238	—	0.991	Q9Z238 →
P25322	—	0.988	P25322 →
P39948	—	0.987	P39948 →
CCND1	G1/S-specific cyclin-D1	0.987	landscape →
Q2KI22	—	0.986	Q2KI22 →
Q5R6J5	—	0.986	Q5R6J5 →
Q5E9K7	—	0.985	Q5E9K7 →
Q64HP0	—	0.984	Q64HP0 →
Q16589	—	0.982	Q16589 →
P55169	—	0.982	P55169 →
Q90459	—	0.982	Q90459 →
P49706	—	0.980	P49706 →
Q0P5D3	—	0.980	Q0P5D3 →
Q8WNW2	—	0.979	Q8WNW2 →
Q9D995	—	0.979	Q9D995 →
P30280	—	0.979	P30280 →
Q7T0L6	—	0.979	Q7T0L6 →
Q8N815	—	0.979	Q8N815 →
P50755	—	0.977	P50755 →
Q04827	—	0.977	Q04827 →
P53782	—	0.976	P53782 →